ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

On Capitol Hill: Cancer Organizations Push Congress For Payment Of Patient Care Costs In Trials

September 17, 1999

DRG Reimbursement Schedules Estimated for High, Low Areas; City Of Hope Added to Exemptions, Other Without Much Hope

November 18, 1983

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

October 9, 1992

NCI Advisory Group Meetings for July

June 27, 1975

Review Group Report: NCI Role In Drug Development Seen As Information Provider

November 6, 1998

House Subcommittee Passes Bush Request for NIH, NCI Budgets.

June 9, 2006